APTEVO THERAPEUTICS INC. - COMMON STOCK WHEN ISSUED. Daily Stock Analysis

Daily Stock Analysis, AQ, APTEVO THERAPEUTICS INC. - COMMON STOCK WHEN ISSUED, priceseries

APTEVO THERAPEUTICS INC. - COMMON STOCK WHEN ISSUED. Daily Stock Analysis
Stock Information
Open
13.25
Close
13.24
High
13.25
Low
13.23
Previous Close
13.24
Daily Price Gain
0.00
YTD High
13.63
YTD High Date
May 15, 2019
YTD Low
7.21
YTD Low Date
Feb 13, 2019
YTD Price Change
4.50
YTD Gain
51.49%
52 Week High
13.63
52 Week High Date
May 15, 2019
52 Week Low
7.21
52 Week Low Date
Feb 13, 2019
52 Week Price Change
3.24
52 Week Gain
32.40%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 25. 2019
8.51
Apr 9. 2019
8.94
11 Trading Days
5.02%
Link
Company Information
Stock Symbol
AQ
Exchange
NASDAQ
Company URL
http://-
Company Phone
206-838-0500
CEO
Marvin L. White
Headquarters
Washington
Business Address
2401 4TH AVE., SUITE 1050, SEATTLE, WA 98121
Sector
-
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001671584
About

Aptevo Therapeutics, Inc. focuses on novel oncology and hematology therapeutics to meaningfully improve patient's lives. It also products in the areas of hematology and infectious diseases, as well as various investigational stage product candidates in immune-oncology. Aptevo Therapeutics was founded on February 22, 2016 and is headquartered in Seattle, WA.

Description

Aptevo Therapeutics Inc., a biotechnology company, provides oncology and hematology therapeutics. Its marketed products include WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn; and HepaGam B used for the prevention of hepatitis-B recurrence following liver transplantation in HBsAg-positive liver transplant patients, and for the treatment following exposure to hepatitis-B. The company's marketed products also comprise VARIZIG for use in treating following exposure to varicella zoster virus, which causes chickenpox in high-risk individuals; and IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its investigational stage product candidates include MOR209/ES414, ES210, ES425, and otlertuzumab used to expand on the utility and effectiveness of therapeutic antibodies; and 5E3 mAb, a monoclonal antibody therapeutic that is in pre-clinical development for Alzheimer's disease. The company was incorporated in 2016 and is based in Seattle, Washington. As of August 01, 2016, Aptevo Therapeutics Inc. operates independently of Emergent BioSolutions, Inc.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading